Traversing Frontline Treatment Options in EGFR-Mutated Non–Small Cell Lung Cancer

Experts explore the evolving standards of care for EGFR-mutated advanced NSCLC, highlighting therapy selection and innovative combination strategies.

The FDA approval of amivantamab and lazertinib transforms frontline treatment for EGFR-mutated lung cancer, enhancing patient outcomes and convenience.

The FDA-approved combination of amivantamab and lazertinib transforms frontline treatment for EGFR-mutated lung cancer, enhancing patient outcomes and convenience.

Explore the impact of CNS metastasis on prognosis in EGFR mutant lung cancer and the promising results from the MARIPOSA trial.

Subcutaneous amivantamab offers significant advantages over IV administration, including reduced infusion reactions and quicker patient turnover in clinics.

Subcutaneous amivantamab offers significant advantages over IV administration, including reduced infusion reactions and quicker patient turnover in clinics.

Experts discuss the potential of amivantamab and velertinib in early-stage lung cancer treatment, emphasizing the need for careful patient management.